The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SRZN | +31.78% | N/A | N/A | -91% |
| S&P | +16.23% | +94.45% | +14.22% | +77% |
Surrozen, Inc. is a clinical stage biotechnology company. It engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.98M | 0.0% |
| Gross Profit | $0.85M | 319.2% |
| Gross Margin | 86.06% | 0.0% |
| Market Cap | $76.55M | 118.5% |
| Market Cap / Employee | $1.87M | 0.0% |
| Employees | 41 | -2.4% |
| Net Income | $21.81M | 186.3% |
| EBITDA | -$8.88M | -2.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $90.39M | 139.3% |
| Accounts Receivable | $2.57M | 21.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.32M | 0.0% |
| Short Term Debt | $1.20M | -44.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -46.88% | 51.1% |
| Return On Invested Capital | 33.58% | 99.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.13M | -9.3% |
| Operating Free Cash Flow | -$6.11M | -8.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 6.34 | 8.23 | -1.78 | 13.38 | 1648.28% |
| Price to Sales | 3.87 | 4.39 | 3.63 | 6.05 | - |
| Price to Tangible Book Value | 6.34 | 8.23 | -1.78 | 13.38 | 1648.28% |
| Enterprise Value to EBITDA | 5.84 | -2.50 | 5.55 | 0.73 | 552.25% |
| Return on Equity | -173.6% | -767.9% | -456.3% | -130.3% | -25.52% |
| Total Debt | $1.53M | $8.47M | $7.97M | $7.51M | 246.91% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
